(PharmaNewsWire.Com, November 09, 2021 ) According to the new market research report sterility testing market is expected to reach USD 941.0 Million by 2021 from USD 528.0 Million in 2016, at a CAGR of 12.3% from 2016 to 2021.
The growth of the sterility testing market can be attributed to the growth in the pharmaceutical and biotechnology industries, increase in the number of new drug launches, and increasing R&D in life science research.
Major players in the sterility testing market include Merck KGaA (Germany), Charles River Laboratories International, Inc. (U.S.), bioMérieux SA (France), SGS S.A. (Switzerland), Sartorius AG (Germany), WuXi AppTec (China), Nelson Laboratories (U.S.), Danaher Corporation (U.S.), Pacific Biolabs (U.S.), Toxikon Corporation (U.S.), and Thermo Fisher Scientific, Inc. (U.S.).
Merck KGaA (Germany) dominated the sterility testing market in 2015. The company’s dominance in the market can be attributed to its robust product portfolio and strong geographic presence. The company focuses on organic as well as inorganic growth strategies for enhancing its market position. In September 2016, the company launched its Steritest Symbio Pump systems to enhance its product portfolio and increase its market presence. Furthermore, the company was focused on inorganic growth strategies. In November 2015, Merck KGaA acquired Sigma-Aldrich Corporation (U.S.); this acquisition helped the company strengthen its sterility testing product portfolio.
Charles River Laboratories International, Inc. (U.S.) held the second position in the sterility testing market in 2015. This can be attributed to the company’s strong sterility testing portfolio. The company adopted organic growth strategies such as mergers and acquisitions to boost its market share. In November 2015, Charles River acquired Celsis International Ltd. (U.S.). This acquisition helped the company to strengthen its microbial detection product portfolio. Also in November 2015, Charles River Laboratories acquired Oncotest GmbH (Germany), a global CRO dedicated to discovery services for oncology. This acquisition strengthened Charles River's portfolio of target discovery & validation services and in vivo pharmacology.
On the basis of product, the Sterility Testing Market is segmented into kits and reagents, instruments, and services. The kits and reagents segment is expected to account for the largest share of the market. The large share of the kits and reagents segment can be attributed to the requirement of the repeat purchase of these products, coupled with the increasing preference for kit-based testing.
On the basis of test, the Sterility Testing Market is segmented into membrane filtration, direct inoculation, and other sterility tests. In 2016, the membrane filtration segment accounted for the largest share. The large share of this segment can primarily be attributed to rapid growth in the pharmaceutical and biotechnology end-use industry.
Market Dynamics -
Drivers
> Growth of pharmaceutical & biotechnology companies > Increasing number of drug launches > Government support for pharmaceutical and biotechnology industries > Increasing R&D investment in life sciences
Restraints
> High degree of consolidation, major barrier for new market entrants > Stringent regulatory frameworks and time-consuming approval processes
Growth of pharmaceutical and biotechnology companies drives the global sterility testing market
In pharmaceutical and biopharmaceutical industries, sterility testing is carried out at all levels of manufacturing to minimize the risk of product contamination. Subsequently, the growth of this end-use industry in the coming years will considerably boost the overall use of sterility testing. With stringent regulatory controls in place, process monitoring and quality control are carried out for the entire production chain of pharmaceutical and biopharmaceutical products. In this process, sterility testing is carried out for raw materials, bulk lot release testing, and final product release testing. According to the International Trade Administration, U.S. Department of Commerce, the global pharmaceuticals market is projected to grow from USD 1 trillion in 2015 to USD 1.3 trillion by 2020 at a CAGR of 4.9%. Strong growth in pharmaceutical and biopharmaceutical industries will drive the sterility testing market.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
